The present invention relates to a new anti-BARF1 monoclonal antibody.

Disclosed are compositions, methods and apparatus for diagnosing and/or monitoring a herpesvirus-associated systemic inflammation by measurement of a host immune response. These compositions, methods and apparatus can be used for diagnosis including early diagnosis, monitoring, making treatment decisions, or management of subjects suspected of having systemic inflammation associated with a herpesvirus infection. More particularly, the present invention discloses peripheral blood RNA and protein biomarkers that are useful for specifically distinguishing between the host systemic immune response to herpesviruses as compared to the host immune response to other causes of systemic inflammation, including other types of viruses.

The invention relates to a method for monitoring the immunological profile of a subject, comprising measuring the expressions of each member of the group consisting of NKp30a, NKp30b, NKp30c, NKp44b and NKp44c, in a biological sample of said subject, wherein: if the expressions of NKp30a, NKp30b, and NKp44b are the three highest among said group, then said subject has a responsive profile; or if the expressions of NKp30c and NKp44c are the two highest among said group, then said subject has an unresponsive profile.

The present invention relates to methods and kits for the prediction and diagnosis of intrauterine-transmission of viral pathogens, specifically, hCMV in a mammalian subject, by calculating the ability of a subject to prevent transmission of said hCMV based on determining the expression of ISG15, IFIT3 and USP18 genes and optionally of EIF2AK2, HERC5, RSAD2 and MX1 genes in a sample of said subject.

The present invention refers to a new monoclonal antibody or fragment thereof, called 11B2C7, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.

Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

Disclosed are vaccine-derived neutralizing antibodies (NAbs) for CMV infections and small peptides which define precise recognition elements of the antigens by the NAbs. In certain embodiments, vaccine-derived NAbs may be produced by immunizing a subject with a gH/gL/UL128/UL130/UL131A pentameric glycoprotein complex (gH/gL-PC). In certain embodiments, vaccine-derived NAbs may have properties similar or identical to those of NAbs induced in a subject naturally infected with CMV. Native and non-native small peptides from UL128 and gH have been defined by mapping epitopes and deriving artificial sequences which are minimal recognition elements of vaccine-derived NAbs disclosed herein. These small peptides can be used to elicit vaccine-derived NAbs that prevent CMV entry into susceptible cell types and protect humans from infection and disease. Multivalent vaccines comprising these small peptides and/or epitopes are also disclosed. Kits and methods of using the vaccine-derived NAbs and small peptides disclosed herein including methods of treating or preventing CMV infection in a subject are also provided.

The present disclosure provides novel serology methods for detecting viremic or latent zoonotic viral infections, such as porcine cytomegalovirus (PCMV) or Porcine lymphotropic herpesvirus (PLHV) infections, in a subject at any stage of development. More specifically, the present disclosure provides an automated multiplexed immunoassay for the rapid and simultaneous detection of one or more anti-PCMV antibodies or anti-PLHV antibodies in biological fluids of a subject suspected of being infected with PCMV or PLHV.